Home›Clinical trials›Florida

GLP-1 clinical trials in Florida: 41 recruiting now

By John Samaras, EditorRegistry checked September 4, 2026

41 GLP-1 clinical trials are recruiting at 228 sites in 64 cities across Florida. Every site below is listed with its city and, where the sponsor publishes one, the number to call.

Every study recruiting in Florida

  1. A Phase 4, Prospective, Open-Label, Single Arm Study to Assess the Effectiveness of Tirzepatide After Initiation of Ixekizumab

    Phase 4. Run by Eli Lilly and Company. Registry number NCT06857942.

    A study testing whether a GLP-1 and GIP medicine from Lilly, tirzepatide, can help people calm psoriasis.

    Who can join. Adults 18+, have psoriasis, BMI 27+.

    5 sites in Florida
    • NeoClinical Research, Hialeah. 305-456-9062
    • Encore Medical Research, Hollywood. 954-400-1725
    • Skin Care Research, Hollywood. 954-674-3535
    • MOORE Clinical Research, Inc. d/b/a TrueBlue Clinical Research, Tampa. 813-948-7550
    • TruDerm & TruSpa, Wellington

  2. A Phase 4, Prospective, Open-Label, Single-Arm Study to Assess the Effectiveness of Tirzepatide After Initiation of Ixekizumab

    Phase 4. Run by Eli Lilly and Company. Registry number NCT06864026.

    A study testing whether a GLP-1 and GIP medicine from Lilly, tirzepatide, can help people ease psoriatic arthritis.

    Who can join. Adults 18+, have psoriatic arthritis, BMI 27+.

    5 sites in Florida
    • Vida Clinical Research, Kissimmee
    • Life Clinical Trials, Margate
    • CZ Rheumatology, Miami Beach
    • Vitalia Medical Research, Palm Beach Gardens. 5615591110
    • International Center for Research, Tampa

  3. PREvention of CardIovascular and DiabEtic kidNey Disease in Type 2 Diabetes

    Phase 4. Run by Brigham and Women's Hospital. Registry number NCT05390892.

    A study testing whether a GLP-1 medicine, semaglutide, can help people lower blood sugar.

    Who can join. Adults 40 to 80, have type 2 diabetes.

    2 sites in Florida

    • Kendall South Medical Center, Inc, Miami. 305-388-1118
    • South Florida Research Solutions, LLC, Pembroke Pines. 954-986-3067

  4. The Impact of GLP Medication on Colonoscopy Bowel Preparation Quality

    Phase 4. Run by The Cleveland Clinic. Registry number NCT07127354.

    A study listed on ClinicalTrials.gov.

    2 sites in Florida

  5. Glucagon-like Peptide-1 Receptor Agonist (GLP-1 RA) and Diet in Inflammatory Bowel Disease (IBD) Patients

    Phase 4. Run by University of Miami. Registry number NCT06774079.

    A study testing whether a GLP-1 and GIP medicine, tirzepatide, can help people with Crohn's disease calm gut inflammation.

    Who can join. Adults 18+, have Crohn's disease, BMI 27+.

    1 site in Florida

  6. The Effect of Tirzepatide on Menopausal Vasomotor Symptoms and Biological Aging in Post-menopausal Women With Obesity

    Phase 4. Run by Mayo Clinic. Registry number NCT07218445.

    A study testing whether a GLP-1 and GIP medicine, tirzepatide, can help women going through menopause lose weight.

    Who can join. Adults 46 to 60, women only, have obesity, BMI 27+.

    1 site in Florida

  7. LIVERAGE™: A Study to Test Whether Survodutide Helps People With a Liver Disease Called NASH/MASH Who Have Moderate or Advanced

    Phase 3. Run by Boehringer Ingelheim. Registry number NCT06632444.

    A study testing whether a GLP-1 and glucagon medicine from Boehringer Ingelheim, survodutide, can help people reduce liver fat.

    Who can join. Adults 18+, have fatty liver disease (also called MASH or NASH) with liver scarring (fibrosis).

    37 sites in Florida

  8. LIVERAGE™ - Cirrhosis: A Study to Test Whether Survodutide Helps People With a Liver Disease Called NASH/MASH Who Have Cirrhosis

    Phase 3. Run by Boehringer Ingelheim. Registry number NCT06632457.

    A study testing whether a GLP-1 and glucagon medicine from Boehringer Ingelheim, survodutide, can help people reduce liver fat.

    Who can join. Adults 18+, have fatty liver disease (also called MASH or NASH), BMI 25+.

    31 sites in Florida

  9. A Master Protocol of Multiple Agents in Adults With Metabolic Dysfunction-Associated Steatotic Liver Disease (SYNERGY-Outcomes)

    Phase 3. Run by Eli Lilly and Company. Registry number NCT07165028.

    A study testing whether a GLP-1, GIP and glucagon medicine from Lilly, retatrutide, can help people reduce liver fat.

    Who can join. Adults 18+, have fatty liver disease (MASLD), BMI 25+.

    23 sites in Florida
    • K2 Medical Research WINTER GARDEN, Clermont. 407-426-9299
    • K2 Medical Research - Daytona Beach, Daytona Beach
    • Care Access - Delray Beach, Delray Beach. 401-773-7855
    • AMR Clinical, Doral
    • Southwest General Healthcare Center, Fort Myers. 239-931-3368
    • University of Florida College of Medicine, Gainesville. 352-273-8662
    • Encore Medical Research, Hollywood. 954-400-1725
    • Nature Coast Clinical Research - Inverness, Inverness. 352-341-2100
    • Encore Borland-Groover Clinical Research, Jacksonville. 904-680-0871
    • Health Awareness, Jupiter
    • K2 MEDICAL Research THE VILLAGES, Lady Lake. 352-500-5252
    • Florida Research Institute, Lakewood Rch. 941-727-7772
    • Tampa Bay Medical Research - Largo, Largo. 727-724-3316
    • Evolution Clinical Trials, Miami. 786-706-1216
    • Floridian Clinical Research, LLC, Miami Lakes. 305-330-9977
    • GI PROS Research, Naples. 239-571-0899
    • Charter Research - Orlando, Orlando
    • Headlands Research Orlando, Orlando. 407-705-3471
    • Progressive Medical Research, Port Orange. 386-304-7070
    • Covenant Metabolic Specialists - Riverview, Riverview. 941-894-2014
    • Care Access - St. Petersburg, St. Petersburg. 877-791-0656
    • Care Access - Tamarac, Tamarac. 877-791-0656
    • Covenant Metabolic Specialists, LLC, University Park. 941-894-2014

  10. A Study to Test Whether Survodutide Helps People With Type 2 Diabetes Control Their Blood Sugar

    Phase 3. Run by Boehringer Ingelheim. Registry number NCT07754461.

    A study testing whether a GLP-1 and glucagon medicine from Boehringer Ingelheim, survodutide, can help people with type 2 diabetes lower blood sugar.

    Who can join. Adults 18+, have type 2 diabetes, BMI 23+.

    15 sites in Florida

  11. A Clinical Study to Compare Efficacy and Safety of Two Different Doses of CagriSema and Semaglutide in Participants With Obesity

    Phase 3. Run by Novo Nordisk A/S. Registry number NCT07564414.

    A study testing whether a study medicine from Novo Nordisk, cagrisema, can help people with type 2 diabetes lose weight.

    Who can join. Adults 18+, have obesity, BMI 35+.

    10 sites in Florida
    • TBMR & Alcanza, Clearwater
    • Northeast Research Institute, Fleming Island
    • Northeast Research Institute, Jacksonville
    • Westside Center For Clinical Research, Jacksonville
    • Bioclinical Research Alliance, Miami
    • New Horizon Research Center, Miami
    • South Broward Research LLC, Miramar
    • West Orange Endocrinology, Ocoee
    • Oviedo Medical Research, LLC, Oviedo
    • Clinical Trial Services Corp, Pembroke Pines

  12. A Phase 3, Open-label Trial to Evaluate the Efficacy, Safety and Tolerability of Switching From the Glucagon-like Peptide-1

    Phase 3. Run by Amgen. Registry number NCT07575399.

    A study testing whether a study medicine from Amgen, Maridebart Cafraglutide, can help people lose weight.

    Who can join. Adults 18+, have obesity or are overweight, BMI 25+.

    9 sites in Florida
    • University of Florida Department of Medicine, Gainesville
    • Aga Clinical Trials, Hialeah
    • South Florida Clinical Research, Margate
    • New Horizon Research Center, Miami
    • Research Institute of South Florida, Miami
    • Clinical Neuroscience Solutions, Orlando
    • Florida Institute for Clinical Research, Orlando
    • Progressive Medical Research, Port Orange
    • Charter Research - The Villages, The Villages

  13. Mirikizumab Administered at the Same Time as Tirzepatide in Adult Participants With Moderately to Severely Active Ulcerative

    Phase 3. Run by Eli Lilly and Company. Registry number NCT06937086.

    A study testing whether a GLP-1 and GIP medicine from Lilly, tirzepatide, can help people with ulcerative colitis calm gut inflammation.

    Who can join. Adults 18 to 70, have ulcerative colitis, BMI 27+.

    6 sites in Florida
    • Gastro Health Research - Miami, Miami
    • Research Associates of South Florida - Miami - Southwest 8th Street, Miami
    • Digestive and Liver Center of Florida, Orlando. 407-384-7388
    • Orlando Health, Orlando
    • Gastro Health Research - Pensacola, Pensacola
    • Precision Clinical Research, Sunrise

  14. Mirikizumab and Tirzepatide Administered in Adult Participants With Moderately to Severely Active Crohn's Disease and Obesity

    Phase 3. Run by Eli Lilly and Company. Registry number NCT06937099.

    A study testing whether a GLP-1 and GIP medicine from Lilly, tirzepatide, can help people with Crohn's disease calm gut inflammation.

    Who can join. Adults 18 to 70, have Crohn's disease, BMI 27+.

    6 sites in Florida
    • Gastro Health Research - Miami, Miami
    • Research Associates of South Florida - Miami - Southwest 8th Street, Miami
    • Digestive and Liver Center of Florida, Orlando. 407-384-7388
    • Orlando Health, Orlando
    • Gastro Health Research - Pensacola, Pensacola
    • Precision Clinical Research, Sunrise

  15. A Randomized, Open-label, Parallel-group Phase III Study to Evaluate the Efficacy, Safety, and Tolerability of Elecoglipron

    Phase 3. Run by AstraZeneca. Registry number NCT07662213.

    A study testing whether a GLP-1 medicine, semaglutide, can help people with type 2 diabetes lower blood sugar.

    Who can join. Adults 18+, have type 2 diabetes, BMI 23+.

    5 sites in Florida
    • Research Site, Crystal River
    • Research Site, Hollywood
    • Research Site, Jacksonville
    • Research Site, Leesburg
    • Research Site, Orlando

  16. A Platform Trial for Pediatric Participants With Obesity or Overweight (LY900040)

    Phase 3. Run by Eli Lilly and Company. Registry number NCT06672549.

    A study testing whether a GLP-1 medicine from Lilly, orforglipron, can help people lose weight.

    Who can join. Children and teens 6 to 17, have obesity.

    4 sites in Florida

    • William A. Shands Hospital at the University of Florida, Gainesville
    • Florida Hospital- Center for Pediatric Research, Orlando
    • Nemours Children's Health, Orlando
    • All Childrens Hospital, St. Petersburg

  17. A Study of Orforglipron in Female Participants With Stress Urinary Incontinence Who Have Obesity or Overweight

    Phase 3. Run by Eli Lilly and Company. Registry number NCT07202884.

    A study testing whether a GLP-1 medicine from Lilly, orforglipron, can help people reduce bladder leaks.

    Who can join. Adults 18+, women only, have stress urinary incontinence (bladder leaks), BMI 27+.

    4 sites in Florida

    • AMR Clinical, Fort Myers. 239-936-4421
    • Altus Research, Lake Worth. 561-641-0404
    • New Age Medical Research Corporation, Miami. 305-596-9901
    • Emerald Coast OBGYN Clinical Research, Panama City

  18. Efficacy and Safety of Orforglipron in Participants With Peripheral Artery Disease

    Phase 3. Run by Eli Lilly and Company. Registry number NCT07223593.

    A study testing whether a GLP-1 medicine from Lilly, orforglipron, can help people improve blood flow in the legs.

    Who can join. Adults 18+, have peripheral artery disease (poor blood flow in the legs), BMI 23+.

    4 sites in Florida

    • Lakeview Institute of Clinical Research, Leesburg. 352-782-0606
    • Floridian Clinical Research, LLC, Miami Lakes. 305-330-9977
    • Inpatient Research Clinic, Miami Lakes. 786-502-4303
    • St Johns Center for Clinical Research, Saint Augustine. 904-209-0043

  19. A Research Study on How Well Cagrilintide and CagriSema Work in Children and Adolescents With Excess Body Weight

    Phase 3. Run by Novo Nordisk A/S. Registry number NCT07253285.

    A study testing whether a study medicine from Novo Nordisk, cagrilintide, can help people lose weight.

    Who can join. Children and teens 8 to 18, are overweight.

    3 sites in Florida

    • Encore Medical Research LLC, Hollywood
    • Jacksonville Ctr for Clin Res, Jacksonville
    • Encore Medical Research of Weston, Weston

  20. Research Study on How Well Oral Semaglutide Works for Weight Loss in Adults With Excess Body Weight

    Phase 3. Run by Novo Nordisk A/S. Registry number NCT07770841.

    A study testing whether a GLP-1 medicine from Novo Nordisk, semaglutide, can help people lose weight.

    Who can join. Adults 18+, are overweight, BMI 27+.

    3 sites in Florida

    • ERG Holding Company, LLC / Evolution Research Group, LLC, Delray Beach
    • ERG Holding Company, LLC / Evolution Research Group, LLC, Fort Myers
    • Jedidiah Clinical Research, Tampa
The other 21 studies recruiting in Florida

  1. Phase 3 Study of the Efficacy, Safety, and Clinical Outcomes of Pemvidutide in MASH

    Phase 3. Run by Altimmune, Inc. Registry number NCT07795164.

    A study testing whether a GLP-1 and glucagon medicine from Altimmune, pemvidutide, can help people reduce liver fat.

    Who can join. Adults 18 to 75, have fatty liver disease (also called MASH or NASH), BMI 23+.

    2 sites in Florida

    • Altimmune Clinical Study Site, Miami
    • Altimmune Clinical Study Site, Ocala

  2. Cessation or Reduction of Alcohol Consumption in Veterans: A Randomized Controlled Trial for Alcohol Use Disorder (CRAVE)

    Phase 3. Run by VA Office of Research and Development. Registry number NCT07218354.

    A study testing whether a GLP-1 medicine, semaglutide, can help people with alcohol use disorder drink less.

    Who can join. Adults 18 to 80, have alcohol use disorder, BMI 21+.

    1 site in Florida

    • Orlando VA Healthcare System, Orlando, FL, Orlando. 407-631-4011

  3. Efficacy and Safety of Ribupatide Administered Once Weekly Compared With Semaglutide and Placebo in Participants Living

    Phase 3. Run by Kailera. Registry number NCT07284979.

    A study testing whether an investigational medicine from Kailera, KAI-9531, can help people lose weight.

    Who can join. Adults 18+, have obesity, BMI 35+.

    1 site in Florida

    • Kailera Clinical Site, Orange City

  4. A Study to Evaluate Tradipitant on Treating Nausea and Vomiting Induced by GLP-1R Agonist Use

    Phase 3. Run by Vanda Pharmaceuticals. Registry number NCT07446439.

    A study testing whether an investigational medicine from Vanda Pharmaceuticals, tradipitant, can help people reduce nausea and vomiting.

    Who can join. Adults 18 to 65, have nausea and vomiting, BMI 25+.

    1 site in Florida

  5. A Master Protocol Study (LY900038) of Multiple Intervention-Specific-Appendices (ISAs) in Adult Participants With Obesity

    Phase 2. Run by Eli Lilly and Company. Registry number NCT06143956.

    A study testing whether an investigational medicine from Lilly, LY3305677, can help people lose weight.

    Who can join. Adults 18 to 75, have obesity, BMI 27+.

    6 sites in Florida
    • Northeast Research Institute (NERI), Fleming Island
    • New Horizon Research Center, Miami. 305-226-3933
    • Indago Research & Health Center, Inc, Miami Lakes. 305-825-6588
    • Suncoast Clinical Research, Inc., New Port Richey. 727-849-4131
    • Charter Research - Winter Park, Orlando. 407-337-3000
    • Charter Research - Lady Lake, The Villages. 352-441-2000

  6. A Research Study Comparing How Well Different Doses of the Medicine NNC0662-0419 Lower Blood Sugar in People With Type 2 Diabetes

    Phase 2. Run by Novo Nordisk A/S. Registry number NCT07415954.

    A study testing whether an investigational medicine from Novo Nordisk, NNC0662-0419, can help people with type 2 diabetes lower blood sugar.

    Who can join. Adults 18 to 75, have type 2 diabetes.

    5 sites in Florida
    • Encore Medical Research LLC, Hollywood
    • Bioclinical Research Alliance, Miami
    • South Broward Research LLC, Miramar
    • West Orange Endocrinology, Ocoee
    • Encore Medical Research of Weston, Weston

  7. A Research Study Comparing How Well Different Doses of the Medicine NNC0519-0130 Can Reduce Kidney Damage in People Living

    Phase 2. Run by Novo Nordisk A/S. Registry number NCT06717698.

    A study testing whether an investigational medicine from Novo Nordisk, NNC0519-0130, can help people with chronic kidney disease protect their kidneys.

    Who can join. Adults 18+, have chronic kidney disease, BMI 27+.

    4 sites in Florida

    • Northeast Research Institute, Fleming Island
    • Encore Medical Research LLC, Hollywood
    • Northeast Research Institute, Saint Augustine
    • Clinical Research of Cent FL, Winter Haven

  8. PLATEAU: Phase 2b Proof-of-Concept Study to Evaluate the Effect on Total Body Weight, Physical Function and Safety of Enobosarm

    Phase 2. Run by Veru Inc. Registry number NCT07446998.

    A study testing whether a GLP-1 medicine, semaglutide, can help people with mobility disability lose weight.

    Who can join. Adults 65+, have obesity or are overweight, BMI 35+.

    4 sites in Florida

  9. Phase 2 Randomized, Double-blind, Placebo-Controlled Trial Assessing the Efficacy and Safety of Icovamenib in Participants

    Phase 2. Run by Biomea Fusion Inc. Registry number NCT07502508.

    A study testing whether an investigational medicine from Biomea Fusion, icovamenib, can help people with type 2 diabetes lower blood sugar.

    Who can join. Adults 18 to 70, have type 2 diabetes, BMI 25+.

    3 sites in Florida

    • Southwest General Healthcare Center, Fort Myers
    • Panax Clinical Research, Miami Lakes
    • Flourish Research Orlando, Winter Park

  10. A Research Study Comparing Different Ways of Increasing the Dose of NNC0662-0419 in Participants With Obesity

    Phase 2. Run by Novo Nordisk A/S. Registry number NCT07639021.

    A study testing whether an investigational medicine from Novo Nordisk, NNC0662-0419, can help people lose weight.

    Who can join. Adults 18+, have obesity, BMI 30+.

    3 sites in Florida

    • Encore Medical Research LLC, Hollywood
    • South Broward Research LLC, Miramar
    • West Orange Endocrinology, Ocoee

  11. A Research Study Comparing How Well Different Doses of the Medicine UBT251 Lower Blood Sugar in People With Type 2 Diabetes

    Phase 2. Run by Novo Nordisk A/S. Registry number NCT07668388.

    A study testing whether an investigational medicine from Novo Nordisk, UBT251, can help people with type 2 diabetes lower blood sugar.

    Who can join. Adults 18 to 75, have type 2 diabetes.

    3 sites in Florida

    • Encore Medical Research LLC, Hollywood
    • South Broward Research LLC, Miramar
    • Encore Medical Research of Weston, Weston

  12. Study of Olatorepatide in Adult Participants Living With Overweight or Obesity Without Diabetes

    Phase 2. Run by Regeneron Pharmaceuticals. Registry number NCT07685808.

    A study testing whether a GLP-1 and GIP medicine from Regeneron Pharmaceuticals, olatorepatide, can help people lose weight.

    Who can join. Adults 18+, have obesity or are overweight, BMI 27+.

    3 sites in Florida

    • K2 Medical Research Maitland LLC, Main Office, Maitland
    • Charter Research LLC - The Villages, The Villages
    • Clinical Site Partners, LLC DBA Flourish Research, Winter Park

  13. Evaluation of Tirzepatide as an Adjunct to Buprenorphine for the Treatment of Opioid Use Disorder

    Phase 2. Run by T. John Winhusen, PhD. Registry number NCT06651177.

    A study testing whether a GLP-1 and GIP medicine, tirzepatide, can help people with opioid use disorder cut down on opioids.

    Who can join. Adults 18+, have opioid use disorder, BMI 23+.

    2 sites in Florida

  14. A Study of LY3457263 Compared With Placebo in Participants With Type 2 Diabetes on a Stable Dose of Semaglutide or Tirzepatide

    Phase 2. Run by Eli Lilly and Company. Registry number NCT06897475.

    A study testing whether an investigational medicine from Lilly, LY3457263, can help people with type 2 diabetes lower blood sugar.

    Who can join. Adults 18 to 75, have type 2 diabetes, BMI 27+.

    2 sites in Florida

  15. A Study to Assess the Efficacy, Safety and Tolerability of AT673 Co-administered With Semaglutide in Adult Participants With Type

    Phase 2. Run by Antag Therapeutics. Registry number NCT07724340.

    A study testing whether an investigational medicine from Antag Therapeutics, AT673, can help people who are overweight lower blood sugar and lose weight.

    Who can join. Adults 18+, have type 2 diabetes, BMI 27+.

    2 sites in Florida

  16. Therapeutic Strategies for Microvascular Dysfunction in Type 1 Diabetes

    Phase 2. Run by AdventHealth Translational Research Institute. Registry number NCT05478707.

    A study testing whether a GLP-1 medicine, dulaglutide, can help people with type 1 diabetes lower blood sugar.

    Who can join. Adults 18 to 40, have type 1 diabetes, BMI 19+.

    1 site in Florida

    • AdventHealth Translational Research Institute, Orlando

  17. A Study to Estimate Early Clinical Efficacy Signals of GLP-1 Agonist Administration in Conjunction With Levonorgestrel

    Phase 2. Run by University of Florida. Registry number NCT07107334.

    A study of a GLP-1 medicine, orforglipron, in people with endometrial cancer.

    Who can join. Adults 18+, women only, have endometrial cancer, BMI 30+.

    1 site in Florida

  18. Evaluation of the Tolerability of Cagrilintide in Participants Not Tolerating GLP-1-RA Therapies Due to Gastrointestinal Adverse

    Phase 1. Run by Novo Nordisk A/S. Registry number NCT07607587.

    A study testing whether a study medicine from Novo Nordisk, cagrilintide, can help people lose weight.

    Who can join. Adults 18+, have obesity, BMI 30+.

    4 sites in Florida

    • Northeast Research Institute, Fleming Island
    • Jacksonville Ctr For Clin Res, Jacksonville
    • Center for Diab,Obes & Metab, Pembroke Pines
    • Encore Medical Research of Weston, Weston

  19. A Study to See How Metabolism is Influenced by Weight Loss Due to Intervention With Cagrilintide and Semaglutide Compared to Diet

    Phase 1. Run by Novo Nordisk A/S. Registry number NCT07184086.

    A study testing whether a study medicine from Novo Nordisk, cagrisema, can help people lose weight.

    Who can join. Adults 18 to 65, have obesity, BMI 30+.

    1 site in Florida

    • Advent Health-Res Inst, Orlando

  20. Prolongation of GLP-1 Adherence When Using Continuous Glucose Monitoring

    Run by Abbott Diabetes Care. Registry number NCT06668935.

    A study in people with diabetes.

    Who can join. Adults 18+, have diabetes.

    2 sites in Florida

    • East Coast Institute for Research, LLC, Jacksonville. 904-854-1354
    • Excellence Medical and Research, Miami Gardens. 786-320-5229

  21. Effects of Glucagon-like Peptide-1 (GLP-1) Agonist in Neuro-reproductive Function in Obese Adolescent Females With Polycystic

    Run by Nemours Children's Clinic. Registry number NCT07169136.

    A study testing whether a GLP-1 medicine, semaglutide, can help people manage PCOS.

    Who can join. Children and teens 12 to 18, women only, have polycystic ovary syndrome (PCOS).

    1 site in Florida

Source: ClinicalTrials.gov, the federal registry, read September 4, 2026. Open a study's registry record before you call: it can close to new participants at any time. GLP Chart does not enroll anyone, is not paid for clinical-trial referrals and has no relationship with any sponsor or site on this page.

Screening for a study can take weeks. If you need the drug now, Strut Health is the cheapest cash route on the chart, from $149 a month. That price buys compounded semaglutide, a pharmacy-made version that is not FDA-approved and is not Wegovy, Ozempic, Zepbound or Mounjaro.

Visit Strut Health ↗

Clinical trials by state

Every state with a GLP-1 study recruiting today. 48 of them.

John Samaras, editor of GLP Chart
John Samaras, Founder and EditorI started GLP Chart after overpaying for a GLP-1 myself. Based in Austin, Texas.
About this siteLinkedInContact
Why you can trust GLP Chart. Same scoring framework applied to every program. No paid placements. We never remove unfavorable information at an advertiser's request. Pricing is pulled from each program's public-facing page every Monday.